| 000 | 01726 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515090430.0 | ||
| 264 | 0 | _c20080826 | |
| 008 | 200808s 0 0 eng d | ||
| 022 | _a0344-5704 | ||
| 024 | 7 |
_a10.1007/s00280-007-0603-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeumer, Jan H | |
| 245 | 0 | 0 |
_aConcentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cJul 2008 |
||
| 300 |
_a363-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 |
_aDNA Modification Methylases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aFloxuridine _xblood |
| 650 | 0 | 4 |
_aFluorouracil _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aTandem Mass Spectrometry |
| 650 | 0 | 4 |
_aTetrahydrouridine _xadministration & dosage |
| 650 | 0 | 4 |
_aUridine _xanalogs & derivatives |
| 700 | 1 | _aParise, Robert A | |
| 700 | 1 | _aNewman, Edward M | |
| 700 | 1 | _aDoroshow, James H | |
| 700 | 1 | _aSynold, Timothy W | |
| 700 | 1 | _aLenz, Heinz-Josef | |
| 700 | 1 | _aEgorin, Merrill J | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 62 _gno. 2 _gp. 363-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-007-0603-8 _zAvailable from publisher's website |
| 999 |
_c17421407 _d17421407 |
||